These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 30255734)
1. Direct-to-consumer marketing of stem cell interventions by Canadian businesses. Turner L Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734 [TBL] [Abstract][Full Text] [Related]
2. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions. Turner L Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145 [TBL] [Abstract][Full Text] [Related]
3. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies. Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC Regen Med; 2023 Nov; 18(11):857-868. PubMed ID: 37867326 [No Abstract] [Full Text] [Related]
4. Beyond "medical tourism": Canadian companies marketing medical travel. Turner L Global Health; 2012 Jun; 8():16. PubMed ID: 22703873 [TBL] [Abstract][Full Text] [Related]
5. US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era. Turner L; Wang JC; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Sahrai V Cytotherapy; 2024 Apr; 26(4):393-403. PubMed ID: 38340106 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies. Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC Regen Med; 2023 Oct; 18(10):781-793. PubMed ID: 37795701 [No Abstract] [Full Text] [Related]
7. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions. Ogbogu U; Du J; Koukio Y BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594 [TBL] [Abstract][Full Text] [Related]
8. Assessing "Cell Therapy" Clinics Offering Treatments of Ocular Conditions using Direct-to-Consumer Marketing Websites in the United States. Nirwan RS; Albini TA; Sridhar J; Flynn HW; Kuriyan AE Ophthalmology; 2019 Oct; 126(10):1350-1355. PubMed ID: 30904542 [TBL] [Abstract][Full Text] [Related]
9. Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes. Asadpour A; Yahaya BH; Bicknell K; Cottrell GS; Widera D Stem Cell Res Ther; 2023 May; 14(1):111. PubMed ID: 37138298 [TBL] [Abstract][Full Text] [Related]
10. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis. Knoepfler PS; Turner LG Regen Med; 2018 Jan; 13(1):19-27. PubMed ID: 29327974 [TBL] [Abstract][Full Text] [Related]
11. Stem cell clinics online: the direct-to-consumer portrayal of stem cell medicine. Lau D; Ogbogu U; Taylor B; Stafinski T; Menon D; Caulfield T Cell Stem Cell; 2008 Dec; 3(6):591-4. PubMed ID: 19041775 [TBL] [Abstract][Full Text] [Related]
12. The direct-to-consumer market for stem cell-based interventions in Australia: exploring the experiences of patients. Waldby C; Hendl T; Kerridge I; Lipworth W; Lysaght T; Munsie M; Stewart C Regen Med; 2020 Jan; 15(1):1238-1249. PubMed ID: 32009513 [TBL] [Abstract][Full Text] [Related]
13. Canadian medical tourism companies that have exited the marketplace: Content analysis of websites used to market transnational medical travel. Turner L Global Health; 2011 Oct; 7():40. PubMed ID: 21995598 [TBL] [Abstract][Full Text] [Related]
14. Online marketing practices of regenerative medicine clinics in US-Mexico border region: a web surveillance study. Chavez J; Shah NA; Ruoss S; Cuomo RE; Ward SR; Mackey TK Stem Cell Res Ther; 2021 Mar; 12(1):189. PubMed ID: 33736697 [TBL] [Abstract][Full Text] [Related]
15. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies. Murdoch B; Zarzeczny A; Caulfield T BMJ Open; 2018 Feb; 8(2):e019414. PubMed ID: 29490963 [TBL] [Abstract][Full Text] [Related]
16. A question of ethics: selling autologous stem cell therapies flaunts professional standards. Munsie M; Hyun I Stem Cell Res; 2014 Nov; 13(3 Pt B):647-53. PubMed ID: 24857592 [TBL] [Abstract][Full Text] [Related]
17. Weighing up the evidence used by direct-to-consumer stem cell businesses. Cook M; Richey A; Brafman DA; Frow EK Stem Cell Reports; 2021 Dec; 16(12):2852-2860. PubMed ID: 34767748 [TBL] [Abstract][Full Text] [Related]
18. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action. Caulfield T; Murdoch B BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026 [TBL] [Abstract][Full Text] [Related]
19. Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims. Turner L; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Wang JC Stem Cell Reports; 2023 Nov; 18(11):2010-2015. PubMed ID: 37890484 [TBL] [Abstract][Full Text] [Related]
20. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Turner L; Knoepfler P Cell Stem Cell; 2016 Aug; 19(2):154-157. PubMed ID: 27374789 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]